605 completed, 155 recruiting, 153 terminated, 90 active not recruiting. 1146 Phase 1, 408 Phase 2.
Follow Prostatic Diseases: new trials by email Literature Review of Prostatic Diseases trials Research Report on Prostatic Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy 177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | CHU de Quebec-Universite Laval | 500 | 2028-03-01 | 2025-03-30 |
| REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants REGN21353, Nezastomig, Sarilumab Prophylaxis (Contingency) - Metastatic Castration-Resistant Prostate Cancer, mCRPC | Phase 1 / Phase 2 | Not yet recruiting | Regeneron Pharmaceuticals | 192 | 2027-06-28 | 2026-09-30 |
| ALT-100 Monoclonal Antibody (mAb) in Bone-Predominant Metastatic Androgen Pathway Modulation Resistant (APMR) Prostate Cancer -- The ALTAR-100 Trial ALT-100 - Prostate Cancer Metastatic to Bone | Phase 1 / Phase 2 | Not yet recruiting | University of Florida | 42 | 2027-01-01 | 2026-11-04 |
| PSMA-specific CAR-T Cell Therapy 4SCAR-PSMA T cells - PSMA Positive Tumors or Tumor Tissues | Phase 1 / Phase 2 | Not yet recruiting | Shenzhen Geno-Immune Medical Institute | 100 | 2026-12-31 | 2026-10-30 |
| IL-18 Armored STEAP1 CAR T Cells for the Treatment of Metastatic Castration Resistant Prostate Cancer FH-STEAP1 IL-18 CAR T cells, Antiandrogen Therapy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 20 | 2026-12-31 | 2026-11-12 |
| COQ10 and Vitamin E for Off-Target Radiation Toxicity Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer | Phase 1 / Phase 2 | Not yet recruiting | University of Nebraska | 200 | 2026-12-01 | 2026-10-08 |
| Escalating Cycle 1 Dose of Lu-177-PSMA-617 for the Treatment of Metastatic Castration Resistant Prostate Cancer Biospecimen Collection, Computed Tomography, Gallium Ga 68 Gozetotide - Metastatic Castration-Resistant Prostate Carcinoma, Stage IVB Prostate Cancer AJCC v8 | Phase 1 | Not yet recruiting | University of Michigan Rogel Cancer Center | 20 | 2026-12-01 | 2026-10-15 |
| Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer Pasritamig - Prostate Cancer | Phase 1 | Not yet recruiting | Fred Hutchinson Cancer Center | 18 | 2026-11-30 | 2026-10-06 |
| Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer Sipuleucel-T, N803 - Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-11-30 | 2026-08-10 |
| STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Not yet recruiting | National Cancer Institute (NCI) | 67 | 2026-11-18 | 2026-11-13 |
| Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 120 | 2026-11-18 | 2026-11-13 |
| Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies CRG-150 - HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | CoRegen, Inc. | 67 | 2026-11-01 | 2026-10-02 |
| Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo - Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | The Methodist Hospital Research Institute | 30 | 2026-11-01 | 2026-09-02 |
| A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors [225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer) | Phase 1 | Recruiting | Aktis Oncology, Inc. | 152 | 2026-11-01 | 2026-11-02 |
| RYZ711 Diagnostic Platform Study RYZ711, PSMA PET/CT - Prostate Cancer (Adenocarcinoma), Adenocarcinoma of the Prostate | Phase 1 / Phase 2 | Recruiting | RayzeBio, Inc. | 116 | 2026-10-05 | 2026-11-12 |
| Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients green tea and quercetin + docetaxel, Placebo + docetaxel - Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 1 / Phase 2 | Recruiting | Charles Drew University of Medicine and Science | 99 | 2026-10-01 | 2026-04-15 |
| Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones Biospecimen Collection, Bone Scan, Computed Tomography - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2026-10-01 | 2026-08-28 | |
| A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer fezolinetant, enzalutamide, apalutamide - Prostate Cancer | Phase 1 | Recruiting | Astellas Pharma Global Development, Inc. | 56 | 2026-09-25 | 2026-10-16 |
| Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer [⁶⁴Cu]Cu-RAX301 Injection - Prostate Cancer | Phase 1 / Phase 2 | Not yet recruiting | RadAlliance Therapeutics, Inc | 52 | 2026-09-15 | 2026-08-14 |
| Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC JANX013, JANX007 - Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC) | Phase 1 | Recruiting | Janux Therapeutics | 110 | 2026-09-10 | 2026-09-17 |
Showing 20 of 1146. Sign in to see all of them.
Prostatic Neoplasms (1064) · Breast Neoplasms (173) · Ovarian Neoplasms (118) · Neoplasms (113) · Carcinoma, Non-Small-Cell Lung (97) · Pancreatic Neoplasms (95) · Neoplasm Metastasis (86) · Colorectal Neoplasms (80) · Lung Neoplasms (69) · Urinary Bladder Neoplasms (68) · Stomach Neoplasms (64) · Melanoma (62) · Prostatic Hyperplasia (61) · Carcinoma, Renal Cell (51) · Esophageal Neoplasms (51)
Genital Diseases (1144) · Urogenital Diseases (1143) · Male Urogenital Diseases (1140) · Genital Diseases, Male (1134) · Neoplasms by Site (1071) · Genital Neoplasms, Male (1069) · Urogenital Neoplasms (1065) · Neoplasms (970) · Female Urogenital Diseases (215) · Female Urogenital Diseases and Pregnancy Complications (215) · Skin and Connective Tissue Diseases (210) · Skin Diseases (209) · Breast Diseases (194) · Neoplasms by Histologic Type (189)
Docetaxel (81) · enzalutamide (56) · Prednisone (55) · Abiraterone Acetate (37) · Magnetic Resonance Spectroscopy (27) · pembrolizumab (27) · abiraterone (23) · Radiotherapy (22) · Leuprolide (21) · Cyclophosphamide (20) · bicalutamide (20) · Goserelin (18) · Biopsy (16) · Pluvicto (16) · Specimen Handling (16)
National Cancer Institute (NCI) (57) · Memorial Sloan Kettering Cancer Center (41) · Janssen Research & Development, LLC (22) · M.D. Anderson Cancer Center (21) · AstraZeneca (20) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (18) · GlaxoSmithKline (16) · Novartis Pharmaceuticals (16) · Weill Medical College of Cornell University (14) · Jonsson Comprehensive Cancer Center (12) · Pfizer (10) · University Health Network, Toronto (10) · Amgen (9) · Jiangsu HengRui Medicine Co., Ltd. (9) · Merck Sharp & Dohme LLC (9)
United States (787) · United Kingdom (88) · Canada (85) · China (78) · Australia (74) · Spain (56) · South Korea (49) · France (46) · Japan (33) · Germany (31) · Netherlands (29) · Italy (22) · Belgium (21) · Denmark (15) · Israel (13)
Rahul Aggarwal, MD (10) · Susan Slovin, MD, PhD (7) · Michael Morris, MD (6) · James L Gulley, M.D. (5) · Scott Tagawa, MD (5)
PMID 33465252, PMID 36383907, PMID 19949018, PMID 20818327, PMID 22002018, PMID 22747660, PMID 25475068, PMID 25974235, PMID 28800206, PMID 35110415, PMID 37496366, PMID 38753757, PMID 38885312, PMID 39853781, PMID 39863139, PMID 41044356, PMID 10661346, PMID 11828001, PMID 12694838, PMID 14504052, PMID 14529764, PMID 14967428, PMID 15590164, PMID 15671557, PMID 15735119, PMID 15936549, PMID 16145049, PMID 16597660, PMID 17707059, PMID 17920349, PMID 18245546, PMID 18384719, PMID 18464023, PMID 18523152, PMID 19192962, PMID 19349545, PMID 19375217, PMID 19499186, PMID 19577865, PMID 19706807, PMID 20068553, PMID 20179219, PMID 20305636, PMID 20346578, PMID 20398037, PMID 20398925, PMID 20407240, PMID 20501622, PMID 20598811, PMID 20824184
2023 (13), 2025 (10), 2017 (9), 2019 (8), 2014 (7), P30CA008748 (6), P30CA072720 (5), 2015 (4), P30CA016672 (4), P30CA033572 (4), P30CA015083 (3), P30CA016056 (3), P30CA093373 (3), P30CA124435 (3), P50CA058204 (3)